Description
Background:
Brolucizumab is a humanized monoclonal antibody designed for the treatment of neovascular (wet) AMD. In comparision to a full antibody or a Fab fragment, Brolucizumab is a single chain antibody fragment maintaining full binding capacity to VEGF-A, with its better stability and solubility allowing for higher doses in a single injection. Intreavitreal anti-VEGF therapy has revolutionized treatment of wet AMD, and Brolucizumab inhibits all isoforms of VEGF-A. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.
Intended Use:
For Estimation of Brolucizumab (BEOVU) in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Brolucizumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Brolucizumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Brolucizumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Brolucizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
Principle:
VEGF-A protein is pre-coated onto microwells. Samples and standards are pipetted into microwells and Brolucizumab present in the sample are bound to the target protein. Then, an Anti-Human IgG conjugated to HRP is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of VEGF-A antibody in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!